Cover Page
Cover Page | 9 Months Ended |
Feb. 28, 2021shares | |
Cover [Abstract] | |
Document Type | 10-Q |
Amendment Flag | false |
Document Period End Date | Feb. 28, 2021 |
Document Fiscal Year Focus | 2021 |
Document Fiscal Period Focus | Q3 |
Current Fiscal Year End Date | --05-31 |
Entity Interactive Data Current | Yes |
Entity Current Reporting Status | Yes |
Entity Registrant Name | NEOGEN CORP |
Entity Central Index Key | 0000711377 |
Trading Symbol | NEOG |
Entity Filer Category | Large Accelerated Filer |
Entity Small Business | false |
Document Quarterly Report | true |
Document Transition Report | false |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 53,511,262 |
Entity File Number | 0-17988 |
Title of 12(b) Security | Common Stock |
Security Exchange Name | NASDAQ |
Entity Incorporation, State or Country Code | MI |
Entity Tax Identification Number | 38-2367843 |
Entity Address, Address Line One | 620 Lesher Place |
Local Phone Number | 372-9200 |
Entity Address, State or Province | MI |
Entity Address, City or Town | Lansing |
City Area Code | 517 |
Entity Address, Postal Zip Code | 48912 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Feb. 28, 2021 | May 31, 2020 |
Current Assets | ||
Cash and cash equivalents | $ 73,482,000 | $ 66,269,000 |
Marketable securities | 279,865,000 | 277,404,000 |
Accounts receivable, net of allowance of $1,400 and $1,350 at February 28, 2021 and May 31, 2020, respectively | 87,241,000 | 84,681,000 |
Inventories | 99,267,000 | 95,053,000 |
Prepaid expenses and other current assets | 15,449,000 | 13,999,000 |
Total Current Assets | 555,304,000 | 537,406,000 |
Net Property and Equipment | 97,981,000 | 78,671,000 |
Other Assets | ||
Right of use assets | 1,269,000 | 1,952,000 |
Goodwill | 133,029,000 | 110,340,000 |
Other non-amortizable intangible assets | 15,441,000 | 15,217,000 |
Amortizable intangible and other assets, net of accumulated amortization of $50,998 and $44,690 at February 28, 2021 and May 31, 2020, respectively | 77,192,000 | 53,596,000 |
Total Assets | 880,216,000 | 797,182,000 |
Current Liabilities | ||
Accounts payable | 23,257,000 | 25,650,000 |
Accrued compensation | 7,928,000 | 7,735,000 |
Income taxes | 0 | 1,456,000 |
Other accruals | 14,757,000 | 13,648,000 |
Total Current Liabilities | 45,942,000 | 48,489,000 |
Deferred Income Taxes | 21,276,000 | 18,125,000 |
Other Non-Current Liabilities | 5,315,000 | 5,391,000 |
Total Liabilities | 72,533,000 | 72,005,000 |
Commitments and Contingencies (note 11) | ||
Equity | ||
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding | 0 | 0 |
Common stock, $0.16 par value, 120,000,000 shares authorized, 53,511,262 and 52,945,841 shares issued and outstanding at February 28, 2021 and May 31, 2020, respectively | 8,562,000 | 8,471,000 |
Additional paid-in capital | 290,118,000 | 257,693,000 |
Accumulated other comprehensive loss | (14,841,000) | (19,709,000) |
Retained earnings | 523,844,000 | 478,722,000 |
Total Stockholders' Equity | 807,683,000 | 725,177,000 |
Total Liabilities and Stockholders' Equity | $ 880,216,000 | $ 797,182,000 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Feb. 28, 2021 | May 31, 2020 |
Accounts receivable, allowance | $ 1,400 | $ 1,350 |
Accumulated Amortization | $ 50,998 | $ 44,690 |
Preferred stock, par value | $ 1 | $ 1 |
Preferred stock, shares authorized | 100,000 | 100,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.16 | $ 0.16 |
Common stock, shares authorized | 120,000,000 | 120,000,000 |
Common stock, shares issued | 53,511,262 | 52,945,841 |
Common stock, shares outstanding | 53,511,262 | 52,945,841 |
Consolidated Statements of Inco
Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | |
Revenues | ||||
Total Revenues | $ 116,709 | $ 99,869 | $ 341,034 | $ 309,096 |
Cost of Revenues | ||||
Total Cost of Revenues | 62,860 | 54,539 | 183,669 | 164,546 |
Gross Margin | 53,849 | 45,330 | 157,365 | 144,550 |
Operating Expenses | ||||
Sales and marketing | 18,693 | 17,675 | 52,938 | 53,206 |
General and administrative | 15,146 | 10,789 | 38,343 | 32,473 |
Research and development | 4,236 | 3,823 | 12,170 | 11,292 |
Total Operating Expenses | 38,075 | 32,287 | 103,451 | 96,971 |
Operating Income | 15,774 | 13,043 | 53,914 | 47,579 |
Other Income (Expense) | ||||
Interest income | 294 | 1,600 | 1,571 | 4,381 |
Other expense | (91) | (393) | (363) | (832) |
Total Other Income | 203 | 1,207 | 1,208 | 3,549 |
Income Before Taxes | 15,977 | 14,250 | 55,122 | 51,128 |
Provision for Income Taxes | 2,600 | 2,050 | 10,000 | 8,000 |
Net Income | $ 13,377 | $ 12,200 | $ 45,122 | $ 43,128 |
Net Income Per Share | ||||
Basic | $ 0.25 | $ 0.23 | $ 0.85 | $ 0.82 |
Diluted | $ 0.25 | $ 0.23 | $ 0.85 | $ 0.82 |
Weighted Average Shares Outstanding | ||||
Basic | 53,413 | 52,795 | 53,132 | 52,463 |
Diluted | 53,695 | 53,048 | 53,384 | 52,783 |
Product Revenues | ||||
Revenues | ||||
Total Revenues | $ 92,816 | $ 77,736 | $ 273,288 | $ 247,071 |
Cost of Revenues | ||||
Total Cost of Revenues | 49,466 | 41,068 | 145,336 | 128,658 |
Service Revenues | ||||
Revenues | ||||
Total Revenues | 23,893 | 22,133 | 67,746 | 62,025 |
Cost of Revenues | ||||
Total Cost of Revenues | $ 13,394 | $ 13,471 | $ 38,333 | $ 35,888 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | |
Net income | $ 13,377 | $ 12,200 | $ 45,122 | $ 43,128 |
Other comprehensive income (loss), net of tax: | ||||
foreign currency translations | 360 | (1,761) | 5,419 | (2,452) |
unrealized gain (loss) on marketable securities | (115) | 172 | (552) | 585 |
Total comprehensive income | $ 13,622 | $ 10,611 | $ 49,989 | $ 41,261 |
Consolidated Statements of Equi
Consolidated Statements of Equity - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income (Loss) | Retained Earnings |
Beginning Balance at May. 31, 2019 | $ 637,899 | $ 8,355 | $ 221,937 | $ (11,640) | $ 419,247 |
Beginning Balance (in shares) at May. 31, 2019 | 52,217 | ||||
Exercise of options and share-based compensation plan | 9,713 | $ 30 | 9,683 | ||
Exercise of options and share-based compensation plan (in shares) | 196 | ||||
Issuance of shares under employee stock purchase plan | 538 | $ 2 | 536 | ||
Issuance of shares under employee stock purchase plan (in shares) | 10 | ||||
Net income | 14,652 | 14,652 | |||
Other comprehensive income (loss) | (2,496) | (2,496) | |||
Ending Balance at Aug. 31, 2019 | 660,306 | $ 8,387 | 232,156 | (14,136) | 433,899 |
Ending Balance (in shares) at Aug. 31, 2019 | 52,423 | ||||
Beginning Balance at May. 31, 2019 | 637,899 | $ 8,355 | 221,937 | (11,640) | 419,247 |
Beginning Balance (in shares) at May. 31, 2019 | 52,217 | ||||
Net income | 43,128 | ||||
Ending Balance at Feb. 29, 2020 | 711,871 | $ 8,466 | 254,537 | (13,507) | 462,375 |
Ending Balance (in shares) at Feb. 29, 2020 | 52,911 | ||||
Beginning Balance at Aug. 31, 2019 | 660,306 | $ 8,387 | 232,156 | (14,136) | 433,899 |
Beginning Balance (in shares) at Aug. 31, 2019 | 52,423 | ||||
Exercise of options and share-based compensation plan | 12,117 | $ 47 | 12,070 | ||
Exercise of options and share-based compensation plan (in shares) | 288 | ||||
Net income | 16,276 | 16,276 | |||
Other comprehensive income (loss) | 2,218 | 2,218 | |||
Ending Balance at Nov. 30, 2019 | 690,917 | $ 8,434 | 244,226 | (11,918) | 450,175 |
Ending Balance (in shares) at Nov. 30, 2019 | 52,711 | ||||
Exercise of options and share-based compensation plan | 9,736 | $ 31 | 9,705 | ||
Exercise of options and share-based compensation plan (in shares) | 188 | ||||
Issuance of shares under employee stock purchase plan | 607 | $ 1 | 606 | ||
Issuance of shares under employee stock purchase plan (in shares) | 12 | ||||
Net income | 12,200 | 12,200 | |||
Other comprehensive income (loss) | (1,589) | (1,589) | |||
Ending Balance at Feb. 29, 2020 | 711,871 | $ 8,466 | 254,537 | (13,507) | 462,375 |
Ending Balance (in shares) at Feb. 29, 2020 | 52,911 | ||||
Beginning Balance at May. 31, 2020 | $ 725,177 | $ 8,471 | 257,693 | (19,709) | 478,722 |
Beginning Balance (in shares) at May. 31, 2020 | 52,945,841 | 52,946 | |||
Exercise of options and share-based compensation plan | $ 5,839 | $ 14 | 5,825 | ||
Exercise of options and share-based compensation plan (in shares) | 86 | ||||
Issuance of shares under employee stock purchase plan | 668 | $ 2 | 666 | ||
Issuance of shares under employee stock purchase plan (in shares) | 9 | ||||
Net income | 15,860 | 15,860 | |||
Other comprehensive income (loss) | 4,002 | 4,002 | |||
Ending Balance at Aug. 31, 2020 | 751,546 | $ 8,487 | 264,184 | (15,707) | 494,582 |
Ending Balance (in shares) at Aug. 31, 2020 | 53,041 | ||||
Beginning Balance at May. 31, 2020 | $ 725,177 | $ 8,471 | 257,693 | (19,709) | 478,722 |
Beginning Balance (in shares) at May. 31, 2020 | 52,945,841 | 52,946 | |||
Net income | $ 45,122 | ||||
Ending Balance at Feb. 28, 2021 | $ 807,683 | $ 8,562 | 290,118 | (14,841) | 523,844 |
Ending Balance (in shares) at Feb. 28, 2021 | 53,511,262 | 53,511 | |||
Beginning Balance at Aug. 31, 2020 | $ 751,546 | $ 8,487 | 264,184 | (15,707) | 494,582 |
Beginning Balance (in shares) at Aug. 31, 2020 | 53,041 | ||||
Exercise of options and share-based compensation plan | 9,343 | $ 32 | 9,311 | ||
Exercise of options and share-based compensation plan (in shares) | 203 | ||||
Net income | 15,885 | 15,885 | |||
Other comprehensive income (loss) | 621 | 621 | |||
Ending Balance at Nov. 30, 2020 | 777,395 | $ 8,519 | 273,495 | (15,086) | 510,467 |
Ending Balance (in shares) at Nov. 30, 2020 | 53,244 | ||||
Exercise of options and share-based compensation plan | 11,030 | $ 31 | 10,999 | 0 | 0 |
Exercise of options and share-based compensation plan (in shares) | 193 | ||||
Issuance of shares under employee stock purchase plan | 720 | $ 2 | 718 | 0 | 0 |
Issuance of shares under employee stock purchase plan (in shares) | 10 | ||||
Issuance of shares for Megazyme acquisition , shares | 64 | ||||
Issuance of shares for Megazyme acquisition , Values | 4,916 | $ 10 | 4,906 | ||
Net income | 13,377 | 0 | 0 | 0 | 13,377 |
Other comprehensive income (loss) | 245 | 0 | 0 | 245 | 0 |
Ending Balance at Feb. 28, 2021 | $ 807,683 | $ 8,562 | $ 290,118 | $ (14,841) | $ 523,844 |
Ending Balance (in shares) at Feb. 28, 2021 | 53,511,262 | 53,511 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 9 Months Ended | |
Feb. 28, 2021 | Feb. 29, 2020 | |
Cash Flows From Operating Activities | ||
Net income | $ 45,122,000 | $ 43,128,000 |
Adjustments to reconcile net income to net cash from operating activities: | ||
Depreciation and amortization | 15,107,000 | 13,542,000 |
Share-based compensation | 4,773,000 | 4,795,000 |
Changes in operating assets and liabilities, net of business acquisitions: | ||
Accounts receivable | 1,019,000 | 3,841,000 |
Inventories | 3,328,000 | (2,238,000) |
Prepaid expenses and other current assets | (1,908,000) | (3,119,000) |
Accounts payable, accruals and other changes | (8,321,000) | 301,000 |
Net Cash From Operating Activities | 59,120,000 | 60,250,000 |
Cash Flows For Investing Activities | ||
Purchases of property, equipment and other non-current intangible assets | (19,393,000) | (16,322,000) |
Proceeds from the sales of marketable securities | 602,233,000 | 300,448,000 |
Purchase of marketable securities | (604,694,000) | (351,002,000) |
Business acquisitions, net of cash acquired | (52,000,000) | (9,701,000) |
Net Cash For Investing Activities | (73,854,000) | (76,577,000) |
Cash Flows From Financing Activities | ||
Exercise of stock options and issuance of employee stock purchase plan shares | 22,801,000 | 27,915,000 |
Net Cash From Financing Activities | 22,801,000 | 27,915,000 |
Effect of Foreign Exchange Rate on Cash | (854,000) | (2,502,000) |
Net Increase In Cash and Cash Equivalents | 7,213,000 | 9,086,000 |
Cash and Cash Equivalents, Beginning of Period | 66,269,000 | 41,688,000 |
Cash and Cash Equivalents, End of Period | $ 73,482,000 | $ 50,774,000 |
Accounting Policies
Accounting Policies | 9 Months Ended |
Feb. 28, 2021 | |
Accounting Policies | 1. ACCOUNTING POLICIES BASIS OF PRESENTATION AND CONSOLIDATION The accompanying unaudited consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying unaudited consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three and nine month periods ended February 28, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2021. For more complete financial information, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K Our functional currency is the U.S. dollar. We translate our non-U.S. Recently Adopted Accounting Standards Financial Instruments - Credit Losses On June 1, 2020, the Company adopted ASU No. 2016-13—Measurement held-to-maturity Fair Value Measurements On June 1, 2020, the Company adopted ASU 2018-13, Cloud Computing Implementation Cost On June 1, 2020, the Company adopted ASU 2018-15, Internal-Use 350-40): Comprehensive Income Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on marketable securities. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments. Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. ESTIMATES AND ASSUMPTIONS The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Accounts Receivable Allowance Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends, current conditions and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts. Inventory The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations. Goodwill and Other Intangible Assets Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants not-to-compete Long-Lived Assets Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations. Equity Compensation Plans Share options awarded to employees, restricted stock units (RSUs) and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, an estimate of award forfeitures, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. For RSUs, we use the intrinsic value method to value the units. To value other equity awards, several recognized valuation models exist; none of these models can be singled out as being the best or most correct. The model applied by us can handle most of the specific features included in the options granted, which are the reason for their use. If different models were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 8. Income Taxes We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year. |
Cash and Marketable Securities
Cash and Marketable Securities | 9 Months Ended |
Feb. 28, 2021 | |
Cash and Cash Equivalents [Abstract] | |
Cash and marketable securities | 2. CASH AND MARKETABLE SECURITIES Cash and Cash Equivalents Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90 days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents. Cash and cash equivalents were $73,482,000 and $66,269,000 at February 28, 2021 and May 31, 2020, respectively. The carrying value of these assets approximates fair value due to the short maturity of these instruments and is classified as Level 1 in the fair value hierarchy. Marketable Securities The Company has marketable securities held by banks or broker-dealers at February 28, 2021. Changes in market value are monitored and recorded on a monthly basis; in the event of a downgrade in credit quality subsequent to purchase, the marketable securities investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable securities portfolio. These securities are classified as available for sale. The primary objective of management’s short-term investment activity is to preserve capital for the purpose of funding current operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the income statement. Adjustments in the fair value of these assets are recorded in other comprehensive income. Marketable Securities as of February 28, 2021 and May 31, 2020 are listed below by classification and remaining maturities. (in thousands) Maturity February 28, May 31, US Treasuries 0 - 90 days $ — $ — 91 - 180 days — — 181 days - 1 year — 2,532 1 - 2 years — — Commercial Paper & Corporate Bonds 0 - 90 days 158,183 133,130 91 - 180 days 81,850 73,824 181 days - 1 year 30,189 43,231 1 - 2 years 1,310 7,839 Certificates of Deposit 0 - 90 days 1,253 1,003 91 - 180 days 3,550 5,184 181 days -1 year 3,277 6,069 1 - 2 years 253 4,592 Total Marketable Securities $ 279,865 $ 277,404 The components of marketable securities at February 28, 2021 are as follows: (in thousands) Amortized Unrealized Unrealized Fair Value US Treasuries $ — $ — $ — $ — Commercial Paper & Corporate Bonds 271,600 185 (253 ) 271,532 Certificates of Deposit 8,284 49 — 8,333 Total Marketable Securities $ 279,884 $ 234 $ (253 ) $ 279,865 The components of marketable securities at May 31, 2020 are as follows: (in thousands) Amortized Unrealized Unrealized Fair Value US Treasuries $ 2,502 $ 30 $ — $ 2,532 Commercial Paper & Corporate Bonds 257,700 347 (23 ) 258,024 Certificates of Deposit 16,648 200 — 16,848 Total Marketable Securities $ 276,850 $ 577 $ (23 ) $ 277,404 |
Inventories
Inventories | 9 Months Ended |
Feb. 28, 2021 | |
Inventories | 3. INVENTORIES Inventories are stated at the lower of cost, determined by the first-in, first-out (in thousands) February 28, May 31, Raw materials $ 46,423 $ 45,058 Work-in-process 7,408 6,887 Finished and purchased goods 45,436 43,108 $ 99,267 $ 95,053 |
Leases
Leases | 9 Months Ended |
Feb. 28, 2021 | |
Leases [Abstract] | |
Leases | 4. LEASES We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all of our leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term. Our lease terms may include options to extend when it is reasonably certain that we will exercise that option. Topic ASC 842 requires the Company to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use Right-of-use non-current non-current We have made certain assumptions and judgments when applying ASC 842, the most significant of which are: • We elected the package of practical expedients available for transition that allow us to not reassess whether expired or existing contracts contain leases under the new definition of a lease, lease classification for expired or existing leases and whether previously capitalized initial direct costs would qualify for capitalization under ASC 842. • We did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the underlying asset. • For all asset classes, we elected to not recognize a right-of-use • For all asset classes, we elected to not separate non-lease non-lease • The determination of the discount rate used in a lease is our incremental borrowing rate that is based on what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. Supplemental balance sheet information related to operating leases was as follows: (in thousands) February 28, May 31, Right of use - assets $ 1,269 $ 1,952 Lease liabilities - current 131 1,054 Lease liabilities - non-current 1,089 913 The weighted average remaining lease term and weighted average discount rate were as follows: February 28, May 31, Weighted average remaining lease term 2.4 years 2.5 years Weighted average discount rate 3.0 % 3.2 % Operating lease expenses are classified as cost of revenues or operating expenses on the consolidated statements of income. The components of lease expense were as follows: Three Months Ended February 28/29, Nine Months Ended February 28/29, (in thousands) 2021 2020 2021 2020 Operating leases $ 372 $ 316 $ 1,017 $ 889 Short term leases 17 25 76 106 Total lease expense $ 389 $ 341 $ 1,093 $ 995 Cash paid for amounts included in the measurement of lease liabilities for operating leases included in cash flows from operations on the statement of cash flows were approximately $946,000 and $868,000 for the nine months ended February 28, 2021 and February 29, 2020, respectively. There were no non-cash right-of-use Undiscounted minimum lease payments as of February 28, 2021 were as follows: Amount Years ending May 31, 2021 (1) $ 133 2022 601 2023 347 2024 176 2025 47 2026 and thereafter — Total lease payments 1,304 Less: imputed interest 84 Total lease liabilities $ 1,220 (1) Excluding the nine months ended February 28, 2021. |
Revenue Recognition
Revenue Recognition | 9 Months Ended |
Feb. 28, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | 5. REVENUE RECOGNITION The Company determines the amount of revenue to be recognized through application of the following steps: • Identification of the contract with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, the Company satisfies the performance obligations. Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognized revenue at a point in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met. Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method, for incentives that are offered to individual customers, and the expected-value method, for programs that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available. The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In such cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by Neogen are recorded in sales and marketing expense. Revenue is recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred. The Company derives revenue from two primary sources—product revenue and service revenue. Product revenue consists of shipments of: • Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation; • Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and • Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities. Revenues for our products are recognized and invoiced when the product is shipped to the customer. Service revenue consists primarily of: • Genomic identification and related interpretive bioinformatic services; and • Other commercial laboratory services. Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer. Payment terms for products and services are generally The following table presents disaggregated revenue by major product and service categories for the three and nine month periods ended February 28, 2021 and February 29, 2020: Three Months ended Nine Months ended (in thousands) 2021 2020 2021 2020 Food Safety Natural Toxins, Allergens & Drug Residues $ 18,255 $ 17,154 $ 57,271 $ 57,950 Bacterial & General Sanitation 10,333 9,413 31,499 31,345 Culture Media & Other 14,888 11,222 39,577 35,259 Rodenticides, Insecticides & Disinfectants 9,644 7,964 27,230 20,859 Genomics Services 5,304 4,745 14,566 12,961 $ 58,424 $ 50,498 $ 170,143 $ 158,374 Animal Safety Life Sciences $ 1,399 $ 1,376 $ 4,122 $ 4,901 Veterinary Instruments & Disposables 12,494 10,799 34,843 32,621 Animal Care & Other 8,873 6,667 25,902 20,859 Rodenticides, Insecticides & Disinfectants 18,085 14,558 56,470 47,462 Genomics Services 17,434 15,971 49,554 44,879 $ 58,285 $ 49,371 $ 170,891 $ 150,722 Total Revenues $ 116,709 $ 99,869 $ 341,034 $ 309,096 |
Net Income per Share
Net Income per Share | 9 Months Ended |
Feb. 28, 2021 | |
Net Income per Share | 6. NET INCOME PER SHARE The calculation of net income per share follows: Three Months Ended Nine Months Ended (in thousands, except per share amounts) 2021 2020 2021 2020 Numerator for basic and diluted net income per share: Net income attributable to Neogen $ 13,377 $ 12,200 $ 45,122 $ 43,128 Denominator for basic net income per share: Weighted average shares 53,413 52,795 53,132 52,463 Effect of dilutive stock options and RSUs 282 253 252 320 Denominator for diluted net income per share 53,695 53,048 53,384 52,783 Net income attributable to Neogen per share: Basic $ 0.25 $ 0.23 $ 0.85 $ 0.82 Diluted $ 0.25 $ 0.23 $ 0.85 $ 0.82 |
Segment Information and Geograp
Segment Information and Geographic Data | 9 Months Ended |
Feb. 28, 2021 | |
Segment Information and Geographic Data | 7. SEGMENT INFORMATION AND GEOGRAPHIC DATA We have two Our international operations in the United Kingdom, Mexico, Brazil, China and India originally focused on the Company’s food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer our complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment. Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences on February 28, 2020, this operation has expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment. The accounting policies of each of the segments are the same as those described in Note 1. Segment information follows: (in thousands) Food Animal Corporate and Total As of and for the three months ended February 28, 2021 Product revenues to external customers $ 51,965 $ 40,851 $ — $ 92,816 Service revenues to external customers 6,459 17,434 — 23,893 Total revenues to external customers 58,424 58,285 — 116,709 Operating income (loss) 7,911 11,657 (3,794 ) 15,774 Total assets 287,690 239,179 353,347 880,216 As of and for the three months ended February 29, 2020 Product revenues to external customers $ 44,450 $ 33,286 $ — $ 77,736 Service revenues to external customers 6,048 16,085 — 22,133 Total revenues to external customers 50,498 49,371 — 99,869 Operating income (loss) 5,881 8,492 (1,330 ) 13,043 Total assets 226,077 219,501 327,923 773,501 (1) Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions. (in thousands) Food Animal Corporate and Total As of and for the nine months ended February 28, 2021 Product revenues to external customers $ 151,951 $ 121,337 $ — $ 273,288 Service revenues to external customers 18,192 49,554 — 67,746 Total revenues to external customers 170,143 170,891 — 341,034 Operating income (loss) 24,834 36,068 (6,988 ) 53,914 As of and for the nine months ended February 29, 2020 Product revenues to external customers $ 141,516 $ 105,555 $ — $ 247,071 Service revenues to external customers 16,858 45,167 — 62,025 Total revenues to external customers 158,374 150,722 — 309,096 Operating income (loss) 24,571 26,521 (3,513 ) 47,579 (1) Includes elimination of intersegment transactions. The following table presents the Company’s revenue disaggregated by geographic location: Three months ended Nine months ended (in thousands) 2021 2020 2021 2020 Domestic $ 70,387 $ 59,762 $ 207,544 $ 186,887 International 46,322 40,107 133,490 122,209 Total revenue 116,709 99,869 341,034 309,096 |
Equity Compensation Plans
Equity Compensation Plans | 9 Months Ended |
Feb. 28, 2021 | |
Equity Compensation Plans | 8. EQUITY COMPENSATION PLANS Incentive and non-qualified three five (Options in thousands) Shares Weighted- Options outstanding June 1, 2020 2,162 $ 55.96 Granted 261 68.47 Exercised (491 ) 44.91 Forfeited (179 ) 57.58 Options outstanding February 28, 2021 1,753 $ 58.41 The weighted-average fair value per share of stock options granted during the first nine months of fiscal years 2021 and 2020, estimated on the date of grant using the Black-Scholes option pricing model, was $15.41 and $15.56, respectively. FY2021 Risk-free interest rate 0.2 % Expected dividend yield 0.0 % Expected stock price volatility 31.3 % Expected option life 3.25 years The Company granted 59,125 restricted stock units (RSUs) to directors, officers and employees under the terms of the 2018 Omnibus Incentive Plan in October 2020, which vest ratably over three R SU non-vested During the three and nine month periods ended February 28, 2021 and February 29, 2020, the Company recorded $1,581,000 and $1,640,000 and $4,773,000 and $4,795,000, respectively, of compensation expense related to its share-based awards. The Company offers eligible employees the option to purchase common stock at a 5% discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of the 2011 Employee Stock Purchase Plan; the discount is recorded in general and administrative expense. Total individual purchases in any year are limited to 10% of compensation. |
Business and Product Line Acqui
Business and Product Line Acquisitions | 9 Months Ended |
Feb. 28, 2021 | |
Business and Product Line Acquisitions | 9. BUSINESS AND PRODUCT LINE ACQUISITIONS The Consolidated Statements of Income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions discussed below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings. On January 1, 2020, the Company acquired all of the stock of Productos Quimicos Magiar, a distributor of Neogen’s Food Safety products for the past 20 years, located in Argentina. This acquisition gives Neogen a direct sales presence in Argentina. Consideration for the purchase was $3,776,000 in net cash, with $3,237,000 paid at closing and $540,000 payable to the former owner on January 1, 2022, and up to $979,000 of contingent consideration, payable in one year, based upon an excess net sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $603,000, inventory of $446,000, machinery and equipment of $36,000, other current assets of $221,000, accounts payable of $383,000, other current liabilities of $312,000, contingent consideration accrual of $640,000, non-current 5- 10 (non-deductible but not earned recorded operation. On January 1, 2020, the Company acquired all of the stock of Productos Quimicos Magiar, a distributor non-current 5-10 (non-deductible but no t earned On January 9, 2020, the Company acquired all non-current 5-10 (non-deductible Scotland On January 31, 2020, the Company acquired all of the stock of Abtek Biologicals Limited, a manufacturer non-current 5-10 (non-deductible On February 28, 2020, the Company acquired the assets of Cell BioSciences, an Australian distributor of food safety and industrial microbiology products. This acquisition gives Neogen a direct sales presence across Australasia for its entire product portfolio. Consideration for the purchase was $3,768,000 in cash, with $3,596,000 paid at closing and $172,000 payable in one year. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $420,000, unearned revenue liability of $13,000, intangible assets of $1,338,000 (with an estimated life of 3 to 10 years) and the remainder to goodwill (non-deductible o On March 26, 2020, the Company acquired the assets of Chile-based Magiar Chilena, a distributor of food animal 5-10 On July 31, 2020, the Company acquired the U.S. (including territories) rights to Elanco’s StandGuard Pour-on On December 30, 2020, the Company acquired all of the stock of Megazyme, Ltd, an Ireland-based company, and its wholly owned U.S. subsidiary, Megazyme, Inc. Megazyme is a manufacturer and supplier of diagnostic assay kits and enzymes to measure dietary fiber, complex carbohydrates and enzymes in food and beverages as well as animal feeds. This acquisition will allow Neogen to expand its commercial relationships across food, feed and beverage companies, and provide additional food quality diagnostic products to commercial labs and food science research institutions. Consideration for the purchase was net cash of $39.8 million paid at closing, $8.6 million of cash payable in two installments in two and four years, $4.9 million of stock issued at closing, and up to $2.5 million of contingent consideration, payable in two installments over the next year, based upon an excess net sales formula. The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $1,339,000, inventory of $5,619,000, net property, plant and equipment of $12,141,000, prepayments of $69,000, accounts payable of $4,000, other current liabilities of $2,405,000, contingent consideration accrual of $2,458,000, non-current 5-10 (non-deductible For each acquisition listed above, the revenues and net income were not considered material and were therefore not disclosed. |
Long Term Debt
Long Term Debt | 9 Months Ended |
Feb. 28, 2021 | |
Long Term Debt | 10. LONG TERM DEBT We have a financing agreement with a bank providing for a $15,000,000 unsecured revolving line of credit, which was amended in the second quarter to extend the expiration to November 30, 2023. There were no 100 |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Feb. 28, 2021 | |
Commitments and Contingencies | 11. COMMITMENTS AND CONTINGENCIES The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. Neogen expenses these annual costs of remediation, which have ranged from $38,000 to $131,000 per year over the past five years. The Company’s estimated liability for these costs was $916,000 at both February 28, 2021 and May 31, 2020, measured on an undiscounted basis over an estimated period of 15 years; $100,000 of the liability is recorded within current liabilities and the remainder is recorded within other non-current The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position. |
Accounting Policies (Policies)
Accounting Policies (Policies) | 9 Months Ended |
Feb. 28, 2021 | |
Basis of presentation and consolidation | BASIS OF PRESENTATION AND CONSOLIDATION The accompanying unaudited consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q S-X. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying unaudited consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three and nine month periods ended February 28, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2021. For more complete financial information, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K Our functional currency is the U.S. dollar. We translate our non-U.S. |
Recently Adopted Accounting Standards | Recently Adopted Accounting Standards Financial Instruments - Credit Losses On June 1, 2020, the Company adopted ASU No. 2016-13—Measurement held-to-maturity Fair Value Measurements On June 1, 2020, the Company adopted ASU 2018-13, Cloud Computing Implementation Cost On June 1, 2020, the Company adopted ASU 2018-15, Internal-Use 350-40): |
Comprehensive Income | Comprehensive Income Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on marketable securities. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments. Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. |
Estimates and assumptions | ESTIMATES AND ASSUMPTIONS The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. |
Accounts Receivable Allowance | Accounts Receivable Allowance Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends, current conditions and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts. |
Inventory | Inventory The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations. |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants not-to-compete |
Long-lived Assets | Long-Lived Assets Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations. |
Equity Compensation Plans | Equity Compensation Plans Share options awarded to employees, restricted stock units (RSUs) and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, an estimate of award forfeitures, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. For RSUs, we use the intrinsic value method to value the units. To value other equity awards, several recognized valuation models exist; none of these models can be singled out as being the best or most correct. The model applied by us can handle most of the specific features included in the options granted, which are the reason for their use. If different models were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 8. |
Income Taxes | Income Taxes We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year. |
Cash and Marketable Securities
Cash and Marketable Securities (Tables) | 9 Months Ended |
Feb. 28, 2021 | |
Cash and Cash Equivalents [Abstract] | |
Schedule Of Classification And Maturities Of Marketable Securities | Marketable Securities as of February 28, 2021 and May 31, 2020 are listed below by classification and remaining maturities. (in thousands) Maturity February 28, May 31, US Treasuries 0 - 90 days $ — $ — 91 - 180 days — — 181 days - 1 year — 2,532 1 - 2 years — — Commercial Paper & Corporate Bonds 0 - 90 days 158,183 133,130 91 - 180 days 81,850 73,824 181 days - 1 year 30,189 43,231 1 - 2 years 1,310 7,839 Certificates of Deposit 0 - 90 days 1,253 1,003 91 - 180 days 3,550 5,184 181 days -1 year 3,277 6,069 1 - 2 years 253 4,592 Total Marketable Securities $ 279,865 $ 277,404 |
Summary of components of marketable securities | The components of marketable securities at February 28, 2021 are as follows: (in thousands) Amortized Unrealized Unrealized Fair Value US Treasuries $ — $ — $ — $ — Commercial Paper & Corporate Bonds 271,600 185 (253 ) 271,532 Certificates of Deposit 8,284 49 — 8,333 Total Marketable Securities $ 279,884 $ 234 $ (253 ) $ 279,865 The components of marketable securities at May 31, 2020 are as follows: (in thousands) Amortized Unrealized Unrealized Fair Value US Treasuries $ 2,502 $ 30 $ — $ 2,532 Commercial Paper & Corporate Bonds 257,700 347 (23 ) 258,024 Certificates of Deposit 16,648 200 — 16,848 Total Marketable Securities $ 276,850 $ 577 $ (23 ) $ 277,404 |
Inventories (Tables)
Inventories (Tables) | 9 Months Ended |
Feb. 28, 2021 | |
Inventories | The components of inventories follow: (in thousands) February 28, May 31, Raw materials $ 46,423 $ 45,058 Work-in-process 7,408 6,887 Finished and purchased goods 45,436 43,108 $ 99,267 $ 95,053 |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Feb. 28, 2021 | |
Supplemental balance sheet information related to operating leases | Supplemental balance sheet information related to operating leases was as follows: (in thousands) February 28, May 31, Right of use - assets $ 1,269 $ 1,952 Lease liabilities - current 131 1,054 Lease liabilities - non-current 1,089 913 |
Weighted average remaining lease term and weighted average discount rate | The weighted average remaining lease term and weighted average discount rate were as follows: February 28, May 31, Weighted average remaining lease term 2.4 years 2.5 years Weighted average discount rate 3.0 % 3.2 % |
Components of lease expense | The components of lease expense were as follows: Three Months Ended February 28/29, Nine Months Ended February 28/29, (in thousands) 2021 2020 2021 2020 Operating leases $ 372 $ 316 $ 1,017 $ 889 Short term leases 17 25 76 106 Total lease expense $ 389 $ 341 $ 1,093 $ 995 |
Undiscounted minimum lease payments | Undiscounted minimum lease payments as of February 28, 2021 were as follows: Amount Years ending May 31, 2021 (1) $ 133 2022 601 2023 347 2024 176 2025 47 2026 and thereafter — Total lease payments 1,304 Less: imputed interest 84 Total lease liabilities $ 1,220 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 9 Months Ended |
Feb. 28, 2021 | |
Disaggregated Revenue | The following table presents the Company’s revenue disaggregated by geographic location: Three months ended Nine months ended (in thousands) 2021 2020 2021 2020 Domestic $ 70,387 $ 59,762 $ 207,544 $ 186,887 International 46,322 40,107 133,490 122,209 Total revenue 116,709 99,869 341,034 309,096 |
Operating Segments [Member] | |
Disaggregated Revenue | The following table presents disaggregated revenue by major product and service categories for the three and nine month periods ended February 28, 2021 and February 29, 2020: Three Months ended Nine Months ended (in thousands) 2021 2020 2021 2020 Food Safety Natural Toxins, Allergens & Drug Residues $ 18,255 $ 17,154 $ 57,271 $ 57,950 Bacterial & General Sanitation 10,333 9,413 31,499 31,345 Culture Media & Other 14,888 11,222 39,577 35,259 Rodenticides, Insecticides & Disinfectants 9,644 7,964 27,230 20,859 Genomics Services 5,304 4,745 14,566 12,961 $ 58,424 $ 50,498 $ 170,143 $ 158,374 Animal Safety Life Sciences $ 1,399 $ 1,376 $ 4,122 $ 4,901 Veterinary Instruments & Disposables 12,494 10,799 34,843 32,621 Animal Care & Other 8,873 6,667 25,902 20,859 Rodenticides, Insecticides & Disinfectants 18,085 14,558 56,470 47,462 Genomics Services 17,434 15,971 49,554 44,879 $ 58,285 $ 49,371 $ 170,891 $ 150,722 Total Revenues $ 116,709 $ 99,869 $ 341,034 $ 309,096 |
Net Income per Share (Tables)
Net Income per Share (Tables) | 9 Months Ended |
Feb. 28, 2021 | |
Calculation of Net Income Per Share | The calculation of net income per share follows: Three Months Ended Nine Months Ended (in thousands, except per share amounts) 2021 2020 2021 2020 Numerator for basic and diluted net income per share: Net income attributable to Neogen $ 13,377 $ 12,200 $ 45,122 $ 43,128 Denominator for basic net income per share: Weighted average shares 53,413 52,795 53,132 52,463 Effect of dilutive stock options and RSUs 282 253 252 320 Denominator for diluted net income per share 53,695 53,048 53,384 52,783 Net income attributable to Neogen per share: Basic $ 0.25 $ 0.23 $ 0.85 $ 0.82 Diluted $ 0.25 $ 0.23 $ 0.85 $ 0.82 |
Segment Information and Geogr_2
Segment Information and Geographic Data (Tables) | 9 Months Ended |
Feb. 28, 2021 | |
Segment Information | Segment information follows: (in thousands) Food Animal Corporate and Total As of and for the three months ended February 28, 2021 Product revenues to external customers $ 51,965 $ 40,851 $ — $ 92,816 Service revenues to external customers 6,459 17,434 — 23,893 Total revenues to external customers 58,424 58,285 — 116,709 Operating income (loss) 7,911 11,657 (3,794 ) 15,774 Total assets 287,690 239,179 353,347 880,216 As of and for the three months ended February 29, 2020 Product revenues to external customers $ 44,450 $ 33,286 $ — $ 77,736 Service revenues to external customers 6,048 16,085 — 22,133 Total revenues to external customers 50,498 49,371 — 99,869 Operating income (loss) 5,881 8,492 (1,330 ) 13,043 Total assets 226,077 219,501 327,923 773,501 (1) Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions. (in thousands) Food Animal Corporate and Total As of and for the nine months ended February 28, 2021 Product revenues to external customers $ 151,951 $ 121,337 $ — $ 273,288 Service revenues to external customers 18,192 49,554 — 67,746 Total revenues to external customers 170,143 170,891 — 341,034 Operating income (loss) 24,834 36,068 (6,988 ) 53,914 As of and for the nine months ended February 29, 2020 Product revenues to external customers $ 141,516 $ 105,555 $ — $ 247,071 Service revenues to external customers 16,858 45,167 — 62,025 Total revenues to external customers 158,374 150,722 — 309,096 Operating income (loss) 24,571 26,521 (3,513 ) 47,579 (1) Includes elimination of intersegment transactions. |
Disaggregated Revenue | The following table presents the Company’s revenue disaggregated by geographic location: Three months ended Nine months ended (in thousands) 2021 2020 2021 2020 Domestic $ 70,387 $ 59,762 $ 207,544 $ 186,887 International 46,322 40,107 133,490 122,209 Total revenue 116,709 99,869 341,034 309,096 |
Equity Compensation Plans (Tabl
Equity Compensation Plans (Tables) | 9 Months Ended |
Feb. 28, 2021 | |
Stock Option Activity | A summary of stock option activity during the nine months ended February 28, 2021 follows: (Options in thousands) Shares Weighted- Options outstanding June 1, 2020 2,162 $ 55.96 Granted 261 68.47 Exercised (491 ) 44.91 Forfeited (179 ) 57.58 Options outstanding February 28, 2021 1,753 $ 58.41 |
Fair Value of Stock Options Granted Estimated Weighted-Average Assumptions | The fair value of stock options granted was estimated using the following weighted-average assumptions. FY2021 Risk-free interest rate 0.2 % Expected dividend yield 0.0 % Expected stock price volatility 31.3 % Expected option life 3.25 years |
Accounting Policies - Additiona
Accounting Policies - Additional Information (Detail) | 9 Months Ended |
Feb. 28, 2021 | |
Minimum | |
Significant Accounting Policies [Line Items] | |
Finite lived intangible assets, useful life | 5 years |
Maximum | |
Significant Accounting Policies [Line Items] | |
Finite lived intangible assets, useful life | 25 years |
Cash and Marketable Securitie_2
Cash and Marketable Securities - Additional Information (Detail) - USD ($) | 9 Months Ended | |||
Feb. 28, 2021 | May 31, 2020 | Feb. 29, 2020 | May 31, 2019 | |
Cash and Cash Equivalents [Line Items] | ||||
Marketable securities, maturity period | 90 days | |||
Cash and cash equivalents | $ 73,482,000 | $ 66,269,000 | $ 50,774,000 | $ 41,688,000 |
Marketable Securities (Detail)
Marketable Securities (Detail) - USD ($) $ in Thousands | Feb. 28, 2021 | May 31, 2020 |
Marketable Securities, Current | $ 279,865 | $ 277,404 |
US Treasury Securities | Maturing in 0 - 90 days | ||
Marketable Securities, Current | 0 | 0 |
US Treasury Securities | Maturing in 91 - 180 days | ||
Marketable Securities, Current | 0 | 0 |
US Treasury Securities | Maturing in 181 days - 1 year | ||
Marketable Securities, Current | 0 | 2,532 |
US Treasury Securities | Maturing in 1 - 2 years | ||
Marketable Securities, Current | 0 | 0 |
Commercial Paper | Maturing in 0 - 90 days | ||
Marketable Securities, Current | 158,183 | 133,130 |
Commercial Paper | Maturing in 91 - 180 days | ||
Marketable Securities, Current | 81,850 | 73,824 |
Commercial Paper | Maturing in 181 days - 1 year | ||
Marketable Securities, Current | 30,189 | 43,231 |
Commercial Paper | Maturing in 1 - 2 years | ||
Marketable Securities, Current | 1,310 | 7,839 |
Certificates of Deposit | Maturing in 0 - 90 days | ||
Marketable Securities, Current | 1,253 | 1,003 |
Certificates of Deposit | Maturing in 91 - 180 days | ||
Marketable Securities, Current | 3,550 | 5,184 |
Certificates of Deposit | Maturing in 181 days - 1 year | ||
Marketable Securities, Current | 3,277 | 6,069 |
Certificates of Deposit | Maturing in 1 - 2 years | ||
Marketable Securities, Current | $ 253 | $ 4,592 |
Components of marketable securi
Components of marketable securities (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Feb. 28, 2021 | May 31, 2020 | |
Marketable Securities [Line Items] | ||
Amortized Cost | $ 279,884 | $ 276,850 |
Unrealized gains | 234 | 577 |
Unrealized Losses | (253) | (23) |
Fair Value | 279,865 | 277,404 |
US Treasury Securities [Member] | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 0 | 2,502 |
Unrealized gains | 0 | 30 |
Unrealized Losses | 0 | |
Fair Value | 0 | 2,532 |
Commercial Paper And Corporate Bonds [Member] | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 271,600 | 257,700 |
Unrealized gains | 185 | 347 |
Unrealized Losses | (253) | (23) |
Fair Value | 271,532 | 258,024 |
Certificates of Deposit [Member] | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 8,284 | 16,648 |
Unrealized gains | 49 | 200 |
Unrealized Losses | 0 | |
Fair Value | $ 8,333 | $ 16,848 |
Inventories (Detail)
Inventories (Detail) - USD ($) $ in Thousands | Feb. 28, 2021 | May 31, 2020 |
Inventory [Line Items] | ||
Raw Materials | $ 46,423 | $ 45,058 |
Work-in-process | 7,408 | 6,887 |
Finished and purchased goods | 45,436 | 43,108 |
Inventories | $ 99,267 | $ 95,053 |
Supplemental Balance Sheet Info
Supplemental Balance Sheet Information Related to Operating Leases (Detail) - USD ($) $ in Thousands | Feb. 28, 2021 | May 31, 2020 |
Right of use - assets | $ 1,269 | $ 1,952 |
Lease liabilities - current | 131 | 1,054 |
Lease liabilities - non-current | $ 1,089 | $ 913 |
Weighted Average Remaining Leas
Weighted Average Remaining Lease Term and Weighted Average Discount Rate (Detail) | Feb. 28, 2021 | May 31, 2020 |
Weighted average remaining lease term | 2 years 4 months 24 days | 2 years 6 months |
Weighted average discount rate | 3.00% | 3.20% |
Components of Lease Expense (De
Components of Lease Expense (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | |
Operating leases | $ 372 | $ 316 | $ 1,017 | $ 889 |
Short term leases | 17 | 25 | 76 | 106 |
Total lease expense | $ 389 | $ 341 | $ 1,093 | $ 995 |
Undiscounted Minimum Lease Paym
Undiscounted Minimum Lease Payments (Detail) $ in Thousands | Feb. 28, 2021USD ($) |
Years ending May 31, 2021 | $ 133 |
2022 | 601 |
2023 | 347 |
2024 | 176 |
2025 | 47 |
2026 and thereafter | 0 |
Total lease payments | 1,304 |
Less: imputed interest | 84 |
Total lease liabilities | $ 1,220 |
Leases - Additional Information
Leases - Additional Information (Detail) - USD ($) | 9 Months Ended | |
Feb. 28, 2021 | Feb. 29, 2020 | |
Operating lease payments | $ 946,000 | $ 868,000 |
Revenue Recognition- Additional
Revenue Recognition- Additional Information (Detail) | 9 Months Ended |
Feb. 28, 2021 | |
Products and Services, Payment Terms | 30 to 60 days |
Disaggregated Revenue (Detail)
Disaggregated Revenue (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | Feb. 29, 2020 | |
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | $ 116,709 | $ 99,869 | $ 341,034 | $ 309,096 | $ 309,096 |
Food Safety | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 58,424 | 50,498 | 170,143 | 158,374 | |
Food Safety | Natural Toxins, Allergens & Drug Residues | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 18,255 | 17,154 | 57,271 | 57,950 | |
Food Safety | Bacterial & General Sanitation | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 10,333 | 9,413 | 31,499 | 31,345 | |
Food Safety | Culture Media & Other | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 14,888 | 11,222 | 39,577 | 35,259 | |
Food Safety | Rodenticides, Insecticides & Disinfectants | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 9,644 | 7,964 | 27,230 | 20,859 | |
Food Safety | Genomics Services | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 5,304 | 4,745 | 14,566 | 12,961 | |
Animal Safety | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 58,285 | 49,371 | 170,891 | 150,722 | |
Animal Safety | Life Sciences | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 1,399 | 1,376 | 4,122 | 4,901 | |
Animal Safety | Animal Care & Other | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 8,873 | 6,667 | 25,902 | 20,859 | |
Animal Safety | Veterinary Instruments & Disposables | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 12,494 | 10,799 | 34,843 | 32,621 | |
Animal Safety | Rodenticides, Insecticides & Disinfectants | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | 18,085 | 14,558 | 56,470 | 47,462 | |
Animal Safety | Genomics Services | |||||
Disaggregation of Revenue [Line Items] | |||||
Total Revenues | $ 17,434 | $ 15,971 | $ 49,554 | $ 44,879 |
Calculation of Net Income Per S
Calculation of Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | |
Earnings Per Share [Line Items] | ||||
Numerator for basic and diluted net income per share - Net income attributable to Neogen | $ 13,377 | $ 12,200 | $ 45,122 | $ 43,128 |
Denominator for basic net income per share - Weighted average shares | 53,413 | 52,795 | 53,132 | 52,463 |
Effect of dilutive stock options and RSUs | 282 | 253 | 252 | 320 |
Denominator for diluted net income per share | 53,695 | 53,048 | 53,384 | 52,783 |
Net income attributable to Neogen per share: | ||||
Basic | $ 0.25 | $ 0.23 | $ 0.85 | $ 0.82 |
Diluted | $ 0.25 | $ 0.23 | $ 0.85 | $ 0.82 |
Segment Information and Geogr_3
Segment Information and Geographic Data (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | May 31, 2020 | |
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | $ 341,034 | $ 309,096 | |||
Operating income (loss) | $ 15,774 | $ 13,043 | 53,914 | 47,579 | |
Total Assets | 880,216 | 880,216 | $ 797,182 | ||
Operating Segments | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 116,709 | 99,869 | |||
Operating income (loss) | 15,774 | 13,043 | |||
Total Assets | 880,216 | 773,501 | 880,216 | 773,501 | |
Operating Segments | Corporate and Eliminations | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 0 | 0 | |||
Operating income (loss) | (3,794) | (1,330) | (6,988) | (3,513) | |
Total Assets | 353,347 | 327,923 | 353,347 | 327,923 | |
Operating Segments | Food Safety | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 58,424 | 50,498 | 170,143 | 158,374 | |
Operating income (loss) | 7,911 | 5,881 | 24,834 | 24,571 | |
Total Assets | 287,690 | 226,077 | 287,690 | 226,077 | |
Operating Segments | Food Safety | Corporate and Eliminations | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 0 | ||||
Operating Segments | Animal Safety | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 58,285 | 49,371 | 170,891 | 150,722 | |
Operating income (loss) | 11,657 | 8,492 | 36,068 | 26,521 | |
Total Assets | 239,179 | 219,501 | 239,179 | 219,501 | |
Operating Segments | Animal Safety | Corporate and Eliminations | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 0 | ||||
Product Revenues | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 273,288 | 247,071 | |||
Product Revenues | Operating Segments | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 92,816 | 77,736 | |||
Product Revenues | Operating Segments | Corporate and Eliminations | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 0 | ||||
Product Revenues | Operating Segments | Food Safety | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 51,965 | 44,450 | 151,951 | 141,516 | |
Product Revenues | Operating Segments | Animal Safety | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 40,851 | 33,286 | 121,337 | 105,555 | |
Service Revenues | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 67,746 | 62,025 | |||
Service Revenues | Operating Segments | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 23,893 | 22,133 | |||
Service Revenues | Operating Segments | Corporate and Eliminations | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 0 | ||||
Service Revenues | Operating Segments | Food Safety | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | 6,459 | 6,048 | 18,192 | 16,858 | |
Service Revenues | Operating Segments | Animal Safety | |||||
Segment Reporting Information [Line Items] | |||||
Product revenues to external customers | $ 17,434 | $ 16,085 | $ 49,554 | $ 45,167 |
Segment Information and Geogr_4
Segment Information and Geographic Data - Additional Information (Detail) | 9 Months Ended |
Feb. 28, 2021Segment | |
Segment Reporting Information [Line Items] | |
Number of reportable segments | Segment | 2 |
Disaggregated Revenue by Geogra
Disaggregated Revenue by Geographic Location (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | Feb. 29, 2020 | |
Revenues by Geographic Location [Line Items] | |||||
Total revenue | $ 116,709 | $ 99,869 | $ 341,034 | $ 309,096 | $ 309,096 |
Domestic | |||||
Revenues by Geographic Location [Line Items] | |||||
Total revenue | 70,387 | 59,762 | 207,544 | 186,887 | |
International | |||||
Revenues by Geographic Location [Line Items] | |||||
Total revenue | $ 46,322 | $ 40,107 | $ 133,490 | $ 122,209 |
Stock Option Activity (Detail)
Stock Option Activity (Detail) | 9 Months Ended |
Feb. 28, 2021$ / sharesshares | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | |
Options Outstanding, Beginning Balance | shares | 2,162,000 |
Options, Granted | shares | 261,000 |
Options, Exercised | shares | (491,000) |
Options, Forfeited | shares | (179,000) |
Options Outstanding, Ending Balance | shares | 1,753,000 |
Weighted-Average Exercise Price, Beginning Balance | $ / shares | $ 55.96 |
Weighted-Average Exercise Price, Granted | $ / shares | 68,470 |
Weighted-Average Exercise Price, Exercised | $ / shares | 44,910 |
Weighted-Average Exercise Price, Forfeited | $ / shares | 57,580 |
Weighted-Average Exercise Price, Ending Balance | $ / shares | $ 58.41 |
Fair Value of Stock Options Gra
Fair Value of Stock Options Granted, Estimated using Weighted-Average Assumptions (Detail) | 9 Months Ended |
Feb. 28, 2021 | |
Schedule of Weighted Average Assumptions for Fair Values of Stock Options [Line Items] | |
Risk-free interest rate | 0.20% |
Expected dividend yield | 0.00% |
Expected stock price volatility | 31.30% |
Expected option life (in years) | 3 years 3 months |
Equity Compensation Plans - Add
Equity Compensation Plans - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Oct. 31, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | Feb. 28, 2021 | Feb. 29, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Weighted-average fair value per share of stock options granted | $ 15.41 | $ 15.56 | |||
Compensation expense related to share based awards | $ 1,581,000 | $ 1,640,000 | $ 4,773,000 | $ 4,795,000 | |
2018 Omnibus Incentive Plan | Restricted Stock Units (RSUs) | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 59,125 | ||||
Weighted-average fair value per share of RSUs | $ 68.43 | ||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 4 years 5 months 26 days | ||||
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $ 3,144,000 | $ 3,144,000 | |||
Employee Stock Purchase Plan | 2011 Employee Stock Purchase Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Annual maximum limit percentage of compensation to purchase shares | 5.00% | ||||
Employee stock purchase plan stock price percentage | 10.00% | ||||
Minimum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock option vesting period | 3 years | ||||
Stock option contractual terms | 5 years | ||||
Minimum | 2018 Omnibus Incentive Plan | Restricted Stock Units (RSUs) | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock option vesting period | 3 years | ||||
Maximum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock option vesting period | 5 years | ||||
Stock option contractual terms | 10 years | ||||
Maximum | 2018 Omnibus Incentive Plan | Restricted Stock Units (RSUs) | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock option vesting period | 5 years |
Business and Product Line Acq_2
Business and Product Line Acquisitions - Additional Information (Detail) - USD ($) | Dec. 30, 2020 | Jul. 31, 2020 | Mar. 26, 2020 | Feb. 28, 2020 | Jan. 31, 2020 | Jan. 09, 2020 | Jan. 01, 2020 | Feb. 28, 2021 | Feb. 28, 2021 | Jan. 31, 2021 |
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | $ 172,000 | |||||||||
Purchase price allocation for inventory | $ 164,000 | |||||||||
Cash payable to former owner for purchase of business | $ 8.6 | |||||||||
Abtek Biologicals Limited | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | $ 1,401,000 | |||||||||
Purchase price allocation for accounts receivable | 135,000 | |||||||||
Purchase price allocation for inventory | 207,000 | |||||||||
Purchase price allocation for land, property and equipment | 105,000 | |||||||||
Purchase price allocation for intangible assets | 484,000 | |||||||||
Purchase price allocation for accounts payable | 118,000 | |||||||||
Purchase price allocation for deferred tax liability | 92,000 | |||||||||
Purchase price allocation for other current liabilities | 34,000 | |||||||||
Cash payable to former owner for purchase of business | 119,000 | $ 119,000 | ||||||||
Cash paid for purchase of business | 1,282,000 | |||||||||
Purchase price allocation for Prepaid Expenses | $ 6,000 | |||||||||
Chile-based Magiar Chilena | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | 400,000 | |||||||||
Purchase price allocation for land, property and equipment | 53,000 | |||||||||
Purchase price allocation for intangible assets | 183,000 | |||||||||
Cash payable to former owner for purchase of business | 50,000 | |||||||||
Cash paid for purchase of business | $ 350,000 | |||||||||
Cash payable to former owner for purchase of business, due date | Mar. 26, 2021 | |||||||||
Beef Cattle And Related Assets [Member] | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | $ 2,351,000 | |||||||||
Purchase price allocation for inventory | 51,000 | |||||||||
Purchase price allocation for intangible assets | $ 2,300,000 | |||||||||
Finite lived intangible assets, useful life | 15 years | |||||||||
Megazyme Ltd and Subsidiary Megazyme Inc [Member] | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | 39.8 | $ 1,229,000 | ||||||||
Contingent consideration potential payment | 2.5 | |||||||||
Purchase price allocation for accounts receivable | 1,339,000 | |||||||||
Purchase price allocation for inventory | 5,619,000 | |||||||||
Purchase price allocation for land, property and equipment | 12,141,000 | |||||||||
Allocation of purchase price for contingent consideration potential payment | 2,458,000 | |||||||||
Purchase price allocation for intangible assets | 19,461,000 | |||||||||
Purchase price allocation for accounts payable | 4,000 | |||||||||
Purchase price allocation for deferred tax liability | 2,389,000 | |||||||||
Purchase price allocation for other current liabilities | 2,405,000 | |||||||||
Purchase price allocation for Prepaid Expenses | 69,000 | |||||||||
Business acquisition Value of equity interest issued | $ 4.9 | |||||||||
ARGENTINA | Productos Quimicos Magiar | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | $ 3,776,000 | |||||||||
Contingent consideration potential payment | 979,000 | |||||||||
Purchase price allocation for accounts receivable | 603,000 | |||||||||
Purchase price allocation for inventory | 446,000 | |||||||||
Purchase price allocation for land, property and equipment | 36,000 | |||||||||
Allocation of purchase price for contingent consideration potential payment | 640,000 | |||||||||
Purchase price allocation for intangible assets | 1,471,000 | |||||||||
Purchase price allocation for accounts payable | 383,000 | |||||||||
Purchase price allocation for deferred tax liability | 441,000 | |||||||||
Purchase price allocation for other current liabilities | 312,000 | |||||||||
Cash payable to former owner for purchase of business | 540,000 | |||||||||
Cash paid for purchase of business | 3,237,000 | |||||||||
Contingent consideration paid | $ 530,000 | |||||||||
Cash payable to former owner for purchase of business, due date | Jan. 1, 2022 | |||||||||
Purchase price allocation for other current assets | $ 221,000 | |||||||||
Gain on Contingent Consideration | 110,000 | |||||||||
URUGUAY | Productos Quimicos Magiar | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | 1,488,000 | |||||||||
Contingent consideration potential payment | 241,000 | |||||||||
Purchase price allocation for accounts receivable | 280,000 | |||||||||
Purchase price allocation for inventory | 174,000 | |||||||||
Purchase price allocation for land, property and equipment | 16,000 | |||||||||
Allocation of purchase price for contingent consideration potential payment | 159,000 | |||||||||
Purchase price allocation for intangible assets | 398,000 | |||||||||
Purchase price allocation for accounts payable | 204,000 | |||||||||
Purchase price allocation for deferred tax liability | 99,000 | |||||||||
Purchase price allocation for other current liabilities | 11,000 | |||||||||
Cash payable to former owner for purchase of business | 210,000 | |||||||||
Cash paid for purchase of business | 1,278,000 | |||||||||
Contingent consideration paid | $ 158,000 | |||||||||
Cash payable to former owner for purchase of business, due date | Jan. 1, 2022 | |||||||||
Purchase price allocation for other current assets | $ 68,000 | |||||||||
Gain on Contingent Consideration | $ 1,000 | |||||||||
ITALY | Diessechem Srl | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | $ 3,455,000 | |||||||||
Purchase price allocation for accounts receivable | 780,000 | |||||||||
Purchase price allocation for inventory | 5,000 | |||||||||
Purchase price allocation for intangible assets | 1,225,000 | |||||||||
Purchase price allocation for accounts payable | 140,000 | |||||||||
Purchase price allocation for deferred tax liability | 294,000 | |||||||||
Purchase price allocation for other current liabilities | 305,000 | |||||||||
Purchase price allocation for other current assets | $ 160,000 | |||||||||
AUSTRALIA | Cell BioSciences | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cash consideration for purchase of business | 3,768,000 | |||||||||
Purchase price allocation for inventory | 420,000 | |||||||||
Allocation of purchase price for contingent consideration potential payment | 13,000 | |||||||||
Purchase price allocation for intangible assets | 1,338,000 | |||||||||
Cash payable to former owner for purchase of business | 172,000 | |||||||||
Cash paid for purchase of business | $ 3,596,000 | |||||||||
Minimum | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 5 years | |||||||||
Minimum | Abtek Biologicals Limited | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 5 years | |||||||||
Minimum | Chile-based Magiar Chilena | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 5 years | |||||||||
Minimum | Megazyme Ltd and Subsidiary Megazyme Inc [Member] | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 5 years | |||||||||
Minimum | ARGENTINA | Productos Quimicos Magiar | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 5 years | |||||||||
Minimum | URUGUAY | Productos Quimicos Magiar | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 5 years | |||||||||
Minimum | ITALY | Diessechem Srl | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 5 years | |||||||||
Minimum | AUSTRALIA | Cell BioSciences | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 3 years | |||||||||
Maximum | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 25 years | |||||||||
Maximum | Abtek Biologicals Limited | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 10 years | |||||||||
Maximum | Chile-based Magiar Chilena | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 10 years | |||||||||
Maximum | Megazyme Ltd and Subsidiary Megazyme Inc [Member] | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 10 years | |||||||||
Maximum | ARGENTINA | Productos Quimicos Magiar | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 10 years | |||||||||
Maximum | URUGUAY | Productos Quimicos Magiar | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 10 years | |||||||||
Maximum | ITALY | Diessechem Srl | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 10 years | |||||||||
Maximum | AUSTRALIA | Cell BioSciences | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Finite lived intangible assets, useful life | 10 years |
Long Term Debt - Additional Inf
Long Term Debt - Additional Information (Detail) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Feb. 28, 2021 | Feb. 28, 2021 | May 31, 2021 | May 31, 2020 | |
Debt Instrument [Line Items] | ||||
Unsecured revolving line of credit, total amount available | $ 15,000,000 | $ 15,000,000 | ||
Unsecured revolving line of credit, maturity date | Nov. 30, 2023 | |||
Unsecured revolving line of credit, interest terms | LIBOR plus 100 basis points | |||
Unsecured revolving line of credit, interest rate | 1.12% | 1.12% | ||
Unsecured revolving line of credit, balance outstanding | $ 0 | |||
Unsecured revolving line of credit, advances | $ 0 | $ 0 | ||
Libor Plus | Unsecured Revolving Line of Credit | ||||
Debt Instrument [Line Items] | ||||
Unsecured revolving line of credit, spread | 1.00% |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) - USD ($) | 9 Months Ended | |
Feb. 28, 2021 | May 31, 2020 | |
Commitments and Contingencies Disclosure [Line Items] | ||
Environmental remediation expense, period of remediation, years | 5 years | |
Estimated liability costs of remediation | $ 916,000 | $ 916,000 |
Estimated liability, measurement period, years | 15 years | |
Estimated liability costs of remediation, current | $ 100,000 | |
Minimum | ||
Commitments and Contingencies Disclosure [Line Items] | ||
Environmental remediation expense | $ 38,000 | |
Maximum | ||
Commitments and Contingencies Disclosure [Line Items] | ||
Environmental remediation expense | $ 131,000 |